Travere Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Travere Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Travere Therapeutics Inc Strategy Report
- Understand Travere Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.
Travere Therapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed | Thiola |
Tiopronin for the treatment of cystinuria | Cholbam |
Cholic Acid for pediatric and adult patients with bile acid synthesis disorders | Chenodal |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Asset Disposal | In September, the company sold its bile acid product portfolio to Mirum Pharmaceuticals. |
2023 | Regulatory Approval | In February, the company secured approval from FDA for FILSPARI(sparsentan), the First and Only Non-immunosuppressive Therapy for the treatment of Reduction of Proteinuria in IgA Nephropathy. |
2022 | Regulatory Approval | In May, the company secured approval from USFDA for Sparsentan for the Treatment of IgA Nephropathy. |
Competitor Comparison
Key Parameters | Travere Therapeutics Inc | AbbVie Inc | SciClone Pharmaceuticals Holdings Ltd | Intercept Pharmaceuticals Inc | Voyager Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | China | United States of America | United States of America |
City | San Diego | North Chicago | Shanghai | Morristown | Lexington |
State/Province | California | Illinois | Shanghai | New Jersey | Massachusetts |
No. of Employees | 380 | 50,000 | 1,050 | 341 | 162 |
Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gary A. Lyons | Chairman | Executive Board | 2016 | 71 |
Eric Dube, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2019 | 50 |
Chris Cline | Chief Financial Officer; Senior Vice President - Investor Relations & Corporate Communications | Senior Management | - | - |
Jula Inrig, M.D | Chief Medical Officer | Senior Management | 2022 | 48 |
Peter Heerma | Chief Commercial Officer | Senior Management | 2019 | 52 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer